Our website uses its own and third parties cookies for a high level of user-friendliness. If you continue to browse and  use this website we will assume that you agree with the policies.

COVID-19

COVID-19

  • Covid-19 Tests
  • Companies
  • Individuals
  • Online consultations Covid-19

Atrys HealthAtrys

  • Español
  • English

Main navigation

  • Company
    • Presentation
    • Mission, vision and values
  • Laboratory
    • Laboratory
    • Test directory
    • Clinical trials and R&D services
    • Quality
    • Team
  • Telemedecine
    • What is telemedicine?
    • Radiology
    • Cardiology Cardiology
    • Ophthalmology
    • Dermatology
  • Radiotherapy
  • R&D
    • R&D
    • LIQUID BIOPSY
    • PROGNOSTIC ALGORITHMS
    • DATA INTEGRATION PLATFORMS
    • ONLINE DIAGNOSIS
    • OTHER PROJECTS
    • R&D services and training agreements
    • Publications and patents
  • Investors
  • News
  • Contact
    • Work with us
  • Private area

  • Español
  • English
  • Company
    • Presentation
    • Mission, vision and values
  • Laboratory
    • Laboratory
    • Test directory
      • Anatomic Pathology
      • Cytology
      • Hematology
      • Diagnostic Second Opinion
    • Clinical trials and R&D services
    • Quality
    • Team
  • Telemedecine
    • What is telemedicine?
    • Radiology
    • Cardiology Cardiology
    • Ophthalmology
    • Dermatology
  • Radiotherapy
  • R&D
    • R&D
    • LIQUID BIOPSY
      • BLI-O
      • S100P
      • Surveprost
      • Aptalung
      • InmunoSIGHT
      • Oncoporecise
      • Glibioliquid
      • Metabreast
      • PREDIAPT
      • ONCLIC
    • PROGNOSTIC ALGORITHMS
      • RADIOPROLIQ
      • 3TR
      • Predictgyn
      • Tradion P
      • Anxarecu
      • Precisesads
      • Oncoexpert
      • Prostatepredict
      • IHC and FISH study of EGFRvIII and PTEN expression in relapsed high grade gliomas
      • Identification of a predictive model for therapeutic guidance in cerebral tumors (gliomas) by means of systems pathology
      • Identificación de un modelo predictivo de opción terapéutica en cáncer de mama mediante la aplicación de la Patología Molecular y de Sistemas
      • Identificación de un modelo predictivo de opción terapéutica en linfomas de célula grande (DLBCL) mediante la aplicación de Patología de Sistemas
    • DATA INTEGRATION PLATFORMS
      • Plataforma de ayuda a la detección temprana de enfermedades infecciosas, mediante la identificación local de patógenos a partir de resultados de analíticas provenientes de laboratorios de análisis mediante técnicas de big data y hacking ético
    • ONLINE DIAGNOSIS
      • Daplia
      • eDCardio
      • eDSalud
      • eHealth areas in Hotels
    • OTHER PROJECTS
      • TheraYAP
      • Gliomatherapy
      • Papiloma
      • Zitomab
      • System of pharmacogenomic evaluation for breast cancer treatment with aromatase inhibitors according to a new application designed by ROVI Laboratories
      • CoVIg3
      • RAP-ID19
    • R&D services and training agreements
    • Publications and patents
      • Methods for prognosis of diffuse large b-cell lymphoma
      • EGFR and PTEN gene alterations predicts survival in patients with brain tumors
      • Monoclonal antibodies for the diagnosis, treatment and/or prevention of brain tumors and brain lesions
  • Investors
  • News
  • Contact
    • Work with us

Private area

MAB - Mercado Alternativo Bursátil

Laboratory

  • Laboratory
  • Test directory
  • Clinical trials and R&D services
  • Quality
  • Team
  • Laboratory
  • Test directory
  • Clinical trials and R&D services
  • Quality
  • Team

Quality

Quality

In recent years, laboratories have been subjected to new quality challenges due to a growing need to ensure technical validity of their results in order to promote the free international marketing of products and services.

Atrys is an accredited laboratory since September 2012 by the National Accreditation Entity (ENAC), in accordance with the UNE-EN-ISO 15189:2013 standards, for conducting tests on pathological anatomy and molecular pathology (laboratory reference N. 1029/LE2012). Atrys was the first laboratory in Spain to be accredited in immunohistochemistry (IHQ) and fluorescence in situ hybridization (FISH)according to ISO 15189. During 2017, the scope of accreditation was extended to the diagnosis of conventional gynecological cytology. Continuing in the line of continuous improvement, we are currently working to include new magnitudes in this scope.

Atrys' Quality Policy defines all the specific objectives to offer a service of excellence for cancer diagnosis and prognosis based on rigor, commitment and continuous improvement.

Environment

Atrys is committed to the preservation of the environment and tries to carry out its activity in a way that produces the least possible environmental impact.

For this, Atrys has an environmental management system in accordance with ISO 14001: 2001 and obtained certification for clinical analysis services in the following specialties: pathological anatomy, hematology, molecular and genetic pathology, for diagnostic or research purposes and development.

The commitments and basic principles on which our environmental behavior is based are included in our Environmental Policy that is kept up to date and can be consulted in the documentation section.
A series of objectives are established annually, in order to improve the environmental performance of the laboratory through its achievement.

The following diagram summarizes the main environmental achievements obtained during 2018 and the objectives set for 2019.

Documents

  • File #13539
  • Scope of the accreditation
  • Certificate of the accreditation 15189
  • Environmental policy
  • Scope of the environmental management system
  • Environmental Management System Certificate
External quality assessment

Since its creation, the laboratory participates in numerous national and international external evaluation programs as a tool to guarantee the quality of its services.

These programs are based on the distribution of test samples that have to be analyzed using the technique to be evaluated. The control center of the quality program analyzes the results, stablishing its suitability.

Results obtained in external quality programs are available to customers.

Among the most outstanding programs are:

  • Program for Quality assessment in Pathology (GCP). Sociedad Española de Anatomía Patológica with the Spanish division of the Internacional Academy of Pathology (SEAP-IAP).
  • Program for External Quality assessment in Hematology (HEMCUAL). Sociedad Española de Hematología y Hemoterapia (SEHH).
  • United Kingdom National External Quality Assessment Service (UKNEQAS).
  • PAP PT Cytopathlogy Program (CAP).
  • ENAC

Responsible for quality and environment:

Rosa Urrutia (rurrutia@atryshealth.com)

  • Laboratory
  • Test directory
  • Clinical trials and R&D services
  • Quality
  • Team
  • Laboratory
  • Test directory
  • Clinical trials and R&D services
  • Quality
  • Team
Atrys logo

Atrys Barcelona

C/Provença 392, planta baixa, 
08025, Barcelona

T: +34 934 815 561

info@atryshealth.com

Atrys Madrid

C/ Velázquez 24, 4ºIzq
28001 Madrid

T: +34 917 819 465

info@atryshealth.com

Atrys Granada

Edificio Genyo (PTCS)

Av. Ilustración 114 
18007  Granada

T: +34 958 715 500, ext. 125

info@atryshealth.com

Atrys Lugo

ICM/Atrys Division

Parque empresarial As Gándaras

Rúa María Barbeito, 61
27003 Lugo, España

T: +34 982 240 944
T: +34 902 212 054

Atrys Bogotá

Edificio Global Medical Center

Calle 116 No. 9 - 72, Oficina 410
Bogotá - Colombia

T: (571) 675 0195
T: 316 525 9414
T: 317 517 9533

teleradiologiadecolombia.com

Atrys Santiago de Chile

ITMS/Atrys Division

Av. Gertrudis Echeñique 30
Las Condes 71
Santiago de Chile

T: +56 (2) 2 437 49 04

www.itms.cl

Atrys Sao Paulo

AxisMed/Atrys Division

Avenida das Nações Unidas, 13.797
Bloco II - 18 andar
São Paulo – SP- Brasil

T: +55 11 3513 – 2924

www.portalaxismed.com.br

 

 

Web design | Legal advice